Zhang, Pin
Xu, Binghe
Gui, Lin
Wang, Wenna
Xiu, Meng
Zhang, Xiao
Sun, Guilan
Zhu, Xiaoyu
Zou, Jianjun
Funding for this research was provided by:
Jiangsu Hengrui Medicine Co., Ltd
Article History
Received: 14 December 2020
Accepted: 19 February 2021
First Online: 12 April 2021
Declarations
:
: This trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved (reference # 15–140/1067) by the ethics committee of the Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing, China) and regulatory authorities. All patients provided written informed consent before enrollment.
: Not applicable.
: BX has received research funding from Jiangsu Hengrui Medicine, served as an advisor or consultant for Novartis and Roche and served on Speaker’s Bureaus for AstraZeneca, Eisai, Pfizer and Roche. XZhang, GS, XZhu and JZ are employees of Jiangsu Hengrui Medicine. Other authors declared no conflict of interests.